Recent public awareness and scientific advances have launched a reversal in the historical trend to virtually ignore the importance of obtaining reliable data from pediatric patients during the process of drug development. The need for well-designed clinical trials in children is now clearly recognized, and a few regulatory bodies have addressed the requirements for the conduct of these trials. Global consensus on the unique issues related to pediatric trials, however, has been lacking. The International Conference on Harmonization recently released a draft of its guideline, “Clinical Investigation of Medicinal Products in the Pediatric Population.” The objective of this paper is to discuss critical issues addressed by the guideline. It begins with a brief overview on the underlying need for the guideline and factors that have contributed to shifting attitudes toward the conduct of pediatric clinical trials. The five major considerations outlined in the guideline are then summarized. The discussion for each of the key areas is supplemented with background information, representative cases, and points for further consideration.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Statement by the Steering Committee. Second Steering Committee Meeting, International Conference on Harmonization. Tokyo. 1990.
Clinical Investigation of Medicinal Products in the Pediatric Population: Draft ICH Consensus Guideline. International Conference on Harmonisation. October 7, 1999.
Shirkey H. Therapeutic orphans. J Pediatr. 1968;72(1):119–120.
Gilman JT. Therapeutic drug monitoring in the neonate and paediatric age group: problems and clinical pharmacokinetic implications. Clin Pharmacokinet. 1990;19:1–10.
Kauffman RE, Kearns GL. Pharmacokinetic studies in paediatric patients: clinical and ethical considerations. Clin Pharmacokinet. 1992;23(1):10–19.
Samara E, Granneman R. Role of population pharmacokinetics in drug development: A pharmaceutical industry perspective. Clin Pharmacokinet. 1997;32(4):294–312.
Reed MD. Optimal sampling theory: an overview of its application to pharmacokinetic studies in infants and children. Pediatrics. 1999;104(5):627–632.
Blumer JL. Developmental pharmacology: past, present and future. Acta Paediatr Jpn. 1996;38(6):555–561.
Leeder JS, Kearns GL. Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am. 1997;44(1):55–77.
Therapeutic Products Directorate guidelines: Inclusion of pediatric subjects in clinical trials. Department of Health: Canada; August 1997.
Note for guidance on clinical investigation of medicinal products in children. CPMP/EWP/462/95. European Agency for the Evaluation of Medicinal Products; September 1997.
Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients: Final rule. Federal Register. 1998;63(231):66631–66672.
Report of the Working Party on Registration of Drugs in Children. Therapeutic Goods Administration, Australian Drug Evaluation Committee; October 1997.
Guidelines for the clinical evaluation of drugs in pediatric patients. Report to the Food and Drug Administration. American Academy of Pediatrics Committee on Drugs, 1998.
Nahata MC. Pediatric drug formulations: a rate-limiting step. Drug Inf J. 1999;33:393–396.
Nahata MC. Lack of pediatric drug formulations. Pediatrics. 1999;104(3):607–609.
Manley MC, Oalman M, Sheiham A. A spoonful of sugar helps the medicine go down? Perspectives on the use of sugar in children’s medicines. Soc Sci Med. 1994;39:833–840.
Schaefer HG, Michaelis I. Biopharmaceutical aspects of anti-infective therapy at the extremes of age. JAntimicrob Chemother. 1994;34(Suppl A):33–42.
Committee on Drugs, American Academy of Pediatrics. Alternative routes of drug administration: advantages and disadvantages. Pediatrics. 1997;100(1):143–152.
McRorie T. Quality drug therapy in children: formulations and delivery. Drug Inf J. 1996;30:1173–1177.
Scott AWM. Non-medicinal ingredients. Drug Safety. 1990;5:95–100.
Committee on Drugs, American Academy of Pediatrics. Inactive ingredients in pharmaceutical products: update. Pediatrics. 1997;99(1):268–278.
Wax PM. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann Intern Med. 1995;15(122):6.
Lesko SM, Mitchell AA. Total bilirubin level in relation to excipients in parenteral morphine sulfate administered to seriously ill newborn infants. Paediatr Perinat Epidemiol. 1994;8(4):401–410.
Leeder JS. Developmental aspects of drug metabolism in children. Drug Inf J. 1996;30:1135–1143.
Marshall JD, Kearns GL. Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther. 1999;66(1):66–75.
Finkelstein JW. The effect of developmental changes in adolescence on drug disposition. J Adolesc Health. 1994;15:612–618.
Morselli PL. Clinical pharmacology of the perinatal period and early infancy. Clin Pharmacokinet. 1989;17(suppl 1):13–28.
Stewart CF, Hampton EM. Effect of maturation on drug disposition in pediatric patients. Clin Pharm. 1987;6(7):548–564.
Simeon JG, Dinicola VF, Ferguson HB. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuro-Psychopharmacol Biol Psychiat. 1990;14:791–795.
Geller B, Cooper TB, Graham DL, et al. Pharmaco-kinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year olds with major depressive disorder. J Am Acad Child Adolesc Psych. 1992;31(1):34–44.
Bishai R, Taddio A, Bar-Oz B, et al. Relative efficacy of amethocaine gel and lidocaine-prilocaine cream for Port-a-Cath puncture in children. Pediatrics. 1999;104(3):e31.
Larsson BA, Tannfeldt G, Lagercrantz H, et al. Alleviation of the pain of venepuncture in neonates. Acta Paediatr. 1998;87(7):774–779.
Butler DR, Kuhn RJ, Chandler MHH. Pharmacokinetics of anti-infective agents in paediatric patients. Clin Pharmacokinet. 1994;26(5):374–395.
Gidding SS, Camp D, Flanagan, MH, et al. A policy regarding research in healthy children. J Pediatr. 1993;123:852–855.
International Conference on Harmonization Good Clinical Practices: Consolidated Guideline. Federal Register. 1997;62(242):66113.
Walson PD. Patient recruitment: US perspective. Pediatrics. 1999;104(3):619–622.
Stein PR. Indices of pain intensity: construct validity among preschoolers. Pediatr Nurs. 1995;1995(21):2.
Pereira AL, Guijnsburg R, de Almeida MF, et al. Validity of behavioral and physiologic parameters for acute pain assessment of term newborn infants. Sao Paulo Med J. 1999;117(2):72–80.
Kemp JP. Study designs and challenges in clinical studies conducted in infants and children with asthma. J Allergy Clin lmunol. 1999;104(4 Pt 2):184–190.
Santanello NC, Davies G, Galant SP, et al. Validation of an asthma symptom diary for interventional studies. Arch Dis Child. 1999;80(5):414–420.
Aylward GP. Understanding and treatment of childhood depression. J Pediatr. 1985;107(1):1–9.
Allen DB. Influence of inhaled corticosteroids on growth: a pediatric endocroinologist’s perspective. Acta Paediatr. 1998;87(2):123–129.
Simar MR. Perinatal exposure to CNS-active medications: neurodevelopmental risks. CNS Drugs. 1999;12(6):451–470.
Specific requirements on content and format of labeling for human prescription drugs; Revision of “Pediatric Use” Subsection in the Labeling; Final rule. Federal Register. 1994;59:64240.
Reed MD, Besunder JB. Developmental pharmacology: ontogenic basis of drug disposition. Pediatr Clin North Am. 1989;36(5):1053–1074.
Berdcl D, Suverkrup R, Hermann G, et al. Total theophylline clearance in childhood: the influence of age-dependent changes in metabolism and elimination. Eur J Pediatr. 1987;146(1):41–43.
Kearns GL. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr. 1995;7:220–233.
Ladd GW. Friendship patterns and peer status during early and middle childhood. Dev Behav Pediatr. 1988;9(4):229–237.
Zarbatany L, Hartmann DP, Rankin DB. The psychological functions of preadolescent peer activities. Child Dev. 1990;61(4):1067–1080.
Amiel SA, Sherwin RS, Simonson DC, et al. Impaired insulin in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med. 1986;315(4):215–219.
Tercyak KPJ, Johnson SB, Kirkpatrick KA, et al. Offering a randomized trial of intensive therapy for IDDM to adolescents. Reasons for refusal, patient characteristics and recruiter effects. Diabetes Care. 1998;21(2):213–215.
Litt IF, Cuskey WR. Compliance with medical regimens during adolescence. Pediatr Clin North Am. 1980;27(1):3–15.
Vanelli M, Chiari G, Adinolfi B, et al. Management of insulin-dependent diabetes mellitus in adolescents. Horm Res. 1997;48(Suppl 4):71–75.
Declaration of Helsinki, revised. World Medical Association. 35th World Medical Assembly, Venice. 1993.
Committee on Drugs, American Academy of Pediatrics. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics. 1995;95(2):286–294.
Convention on the Rights of the Child. UNGA Doc A/RES/44/25. United Nations Assembly; January 1989.
Weithorn LA, Scherer DG, Children’s involvement in research participation decisions: psychological considerations, In: Grodin MA, Glantz LH, eds. Children as Research Subjects: Science, Ethics and Law. New York: Oxford University Press; 1994:133–179.
Report and Recommendations: Research Involving Children. [OS]77-0004. Rockville, MD: Department of Health, Education and Welfare, National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research; 1977.
About this article
Cite this article
Simar, M.R. Pediatric Drug Development: The International Conference on Harmonization Focus on Clinical Investigations in Children. Ther Innov Regul Sci 34, 809–819 (2000). https://doi.org/10.1177/009286150003400317
- Drug development